Sino-American biotech BeiGene (HKEX: 06160) saw its shares close up more than 12% at 112.05 renminbi on Friday, after it reported financial results for the second quarter of 2022, recent business highlights, and anticipated upcoming milestones.
Revenue for the three months ended June 30 was up 127% at $341.6 million, compared to $150.0 million in the same period of 2021.
Operating loss decreased by $35.4 million, or 7.5% to $439.4 million, compared to $474.8 million in the same period last year Net loss was $571.4 million, or $0.43 per share, and $5.56 per American Depositary Share (ADS), compared to $480.3 million, or $0.40 per share, and $5.23 per ADS in the same period of 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze